AUTHOR OF THIS BLOG

DR ANTHONY MELVIN CRASTO, WORLDDRUGTRACKER

DR ANTHONY MELVIN CRASTO Ph.D

DR ANTHONY MELVIN CRASTO, Worlddrugtracker, Born in Mumbai in 1964 and graduated from Mumbai University, Completed his PhD from ICT ,1991, Mumbai, India, in Organic chemistry, The thesis topic was Synthesis of Novel Pyrethroid Analogues, Currently he is working with AFRICURE PHARMA as ADVISOR earlier GLENMARK LS Research centre as consultant,Principal Scientist, Process Research (bulk actives) at Mahape, Navi Mumbai, India. Prior to joining Glenmark, he worked with major multinationals like Hoechst Marion Roussel, now sSanofi, Searle India ltd, now Rpg lifesciences, etc. he is now helping millions, has million hits on google on all organic chemistry websites. His New Drug Approvals, Green Chemistry International, Eurekamoments in organic chemistry are some most read blogs He has hands on experience in initiation and developing novel routes for drug molecules and implementation them on commercial scale over a 32 year tenure, good knowledge of IPM, GMP, Regulatory aspects, he has several international drug patents published worldwide . He gas good proficiency in Technology transfer, Spectroscopy, Stereochemistry, Synthesis, polymorphism etc He suffered a paralytic stroke in dec 2007 and is bound to a wheelchair, this seems to have injected feul in him to help chemists around the world, he is more active than before and is pushing boundaries, he has one lakh connections on all networking sites, He makes himself available to all, contact him on +91 9323115463, amcrasto@gmail.com

API, Impurities and Regulatory aspects

 regulatory, Uncategorized  Comments Off on API, Impurities and Regulatory aspects
Oct 242018
 
Image result for impurities
The impurities in pharmaceuticals are unwanted chemicals that remain with the active pharmaceutical ingredients (APIs) or develop during formulation or upon aging of both API and formulation. The presence of these unwanted chemicals even in trace amount may influence the efficacy and safety of pharmaceutical product
Impurities is defined as an entity of drug substances or drug product that is not chemical entity defined as drug substances an excipients or other additives to drugproduct.

The control of pharmaceutical impurities is currently a critical issue to the pharmaceutical industry. Structure elucidation of pharmaceutical impurities is an important part of the drug product development process. Impurities can have unwanted pharmacological or toxicological effects that seriously impact product quality and patient safety. Potential sources and mechanisms of impurity formation are discussed for both drugs. The International Conference on Harmonization (ICH) has formulated a workable guideline regarding the control of impurities. In this review, a description of different types and origins of impurities in relation to ICH guidelines and, degradation routes, including specific examples, are presented. The article further discusses measures regarding the control of impurities in pharmaceuticals substance and drug product applications.

Impurities in pharmaceuticals are the unwanted chemicals that remain with the active pharmaceutical ingredients (APIs), or develop during formulation, or upon aging of both API and formulated APIs to medicines. The presence of these unwanted chemicals even in small amounts may influence the efficacy and safety of the pharmaceutical products.

According to ICH, an impurity in a drug substance is defined as-“any component of the new drug substance that is not the chemical entity defined as the new drug substance”. There is an ever increasing interest in impurities present in APIs recently, not only purity profile but also impurity profile has become essential as per various regulatory requirements. The presence of the unwanted chemicals, even in small amount, may influence the efficacy and safety of the pharmaceutical products.

“In the pharmaceutical world, an impurity is considered as any other organic material, besides the drug substance, or ingredients, arise out of synthesis or unwanted chemicals that remains with API’s”

The control of pharmaceutical impurities is currently a critical issue to the pharmaceutical industry. The International Conference on Harmonization (ICH) has formulated a workable guideline regarding the control of impurities.

CLASSIFICATIONS OF IMPURITIES:
Impurities have been named differently or classified as per the ICH guidelines as follows:

A] Common names
1. By-products
2. Degradation products
3. Interaction products
4. Intermediates
5. Penultimate intermediates
6. Related products
7. Transformation products

B] United State Pharmacopeia
The United States Pharmacopoeia (USP) classifies impurities in various sections:
1. Impurities in Official Articles
2. Ordinary Impurities
3. Organic Volatile Impurities

C] ICH Terminology
According to ICH guidelines, impurities in the drug substance produced by chemical synthesis can broadly be classified into following three categories –
1. Organic Impurities (Process and Drug related)
2. Inorganic Impurities
3. Residual Solvents

Organic impurities may arise during the manufacturing process and or storage of the drug substance may be identified or unidentified, volatile or non-volatile, and may include
1. Starting materials or intermediates
2. By-products
3. Degradation products

Impurities are found in API’s unless, a proper care is taken in every step involved throughout the multi-step synthesis for example; in paracetamol bulk, there is a limit test for p-aminophenol, which could be a starting material for one manufacturer or be an intermediate for the others. Impurities can also be formed by degradation of the end product during manufacturing of the bulk drugs.

The degradation of penicillin and cephalosporin are well-known examples of degradation products. The presence of a β-lactam ring as well as that of an a-amino in the C6 or C7 side chain plays a critical role in their degradation.

The primary objectives of process chemical research are the development of efficient, scalable, and safe reproducible synthetic routes to drug candidates within the developmental space and acting as a framework for commercial production in order to meet the requirement of various regulatory agencies. Therefore, assessment and control of the impurities in a drug substance and drug product are important aspects of drug development for the development team to obtain various marketing approvals. It is extremely challenging for an organic chemist to identify the impurities which are formed in very small quantities in a drug substance and wearisome if the product is nonpharmacopeial. A study describes the formation, identification, synthesis, and characterization of impurities found in the preparation of API. A study will help a synthetic organic chemist to understand the potential impurities in API synthesis and thereby obtain the pure compound.
Care to taken ensure that desired drug metabolism, safety and clinical studies are not jeopardized by inconsistent purity or impurities having potential harmful toxicological properties,
As regulatory guidelines promulgated by the International Conference on Harmonization (ICH)(1) dictate rigorous identification of impurities at levels of 0.1%,
It is important to develop commercially viable processes for drug substance manufacture to allow greater and more affordable access in the health care sector. In regard to the process development of drug substances, it is essential to know the origin and method of control of any unwanted substances present in it. The limit should be controlled under the threshold of toxicological concern (TTC) for the purpose of ensuring safety and efficacy of the drug and to meet the requirements of various drug regulatory agencies.(2,3)
The impurities in drug substances mostly come from starting substrates, reagents, solvents, and side reactions of the synthetic route employed. Therefore, assessment and control of the undesired substances is an essential aspect of the drug development journey, with special consideration of patient health risk.(4,5)
The isolation/synthesis and characterization of process-related critical impurities (more difficult to control under the desired regulatory limits) of any drug substance in order to evaluate their origin/fate and thereafter their control strategies in the developed process as per International Council for Harmonisation (ICH) guidelines.(4)
The goal of pharmaceutical development is to develop process understanding and control which will yield procedures that consistently deliver products possessing the desired key quality attributes. To achieve this, the quality by design (QbD) paradigm has been employed in combination with process-risk assessment strategies to systematically gather knowledge through the application of sound scientific approaches.(6)
Ganzer et al. recently published an article about critical process parameters and API synthesis.(7) The article presented an in-depth discussion of a stepwise, process risk assessment approach to facilitate the identification and understanding of critical quality attributes, process parameters, and in-process controls. The primary benefit of working within the QbD conceptual framework and employing process risk assessment strategies is the reproducible delivery of high-quality active pharmaceutical ingredient (API). However, a secondary benefit is the ability to obtain regulatory flexibility with respect to filing requirements.(8)
The control of impurities observed in an API is critical in delivering an API of high quality. Identification and understanding of the mechanism of formation of process-related impurities are critical pieces of information required for the development of control strategies. In addition, to ensure a continuing supply of API for drug product clinical manufacture, timely identification of key impurities is essential. These synthesis-related impurities and their precursors are considered as critical impurities because they directly affect the quality and impurity profile of the API. It is our practice that critical impurities be identified if practicable. Therefore, the timely identification of critical impurities becomes an integral part of process development.
There are different approaches to the identification of impurities. Described, herein, a general strategy that we have used in our laboratory, which leads to the rapid identification of impurities. To identify the structure of a low-level unknown impurity, we usually use liquid chromatography/mass spectrometry (LC/MS)/high-resolution MS (HRMS) and tandem MS (MS/MS) for molecular weight (MW) determination, elemental composition, and fragmentation patterns. On the basis of the mass spectrometric data and knowledge of the process chemistry, one or more possible structure(s) may be assigned for the impurity, with definitive structure information obtained by inspection of the HPLC retention time, UV spectrum, and MS profile of an authentic compound.
If an authentic sample is not available, the isolation of a pure sample of the impurity is undertaken for structure elucidation using NMR spectroscopy. The isolation of low-level impurities is usually conducted using preparative HPLC chromatography
REFERENCES
 1 ICH Q3A Impurities in New Drug Substances, R2International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH)Geneva, Switzerland, October 2006http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Quality/Q3A_R2/Step4/Q3A_R2__Guideline.pdf.
  • 2. Patil, G. D.; Kshirsagar, S. W.Shinde, S. B.Patil, P. S.Deshpande, M. S.Chaudhari, A. T.Sonawane, S. P.Maikap, G. C.Gurjar, M. K.Identification, Synthesis, and Strategy For Minimization of Potential Impurities Observed In Raltegravir Potassium Drug SubstanceOrg. Process Res. Dev. 2012161422– 1429DOI: 10.1021/op300077m
  • 3. Huang, Y.; Ye, Q.Guo, Z.Palaniswamy, V. A.Grosso, J. A. Identification of Critical Process Impurities and Their Impact on Process Research and DevelopmentOrg. Process Res. Dev.200812632– 636DOI: 10.1021/op800067v

4. ICH Harmonised Tripartite Guideline Q3A(R): Impurities in New Drug SubstancesInternational Conference on HarmonizationGeneva2002.

5. Mishra, B.Thakur, A.Mahata, P. P. Pharmaceutical Impurities: A ReviewInt. J. Pharm. Chem.20155 (7), 232– 239

6 International Conference on Harmonisation (ICH) Guidelines; Q8, Pharmaceutical Development, 2005; Q9, Quality Risk Management, 2006.

GanzerW. R.MaternaJ. A.MitchellM. B.WallL. K. Pharm. Technol. 2005July 21–12.

NasrM. Drug Information Association Annual Meeting, Philadelphia, PA, June 19, 2006; Pharmaceutical Quality Assessment System (PQAS) in the 21st Century, 2006.

/////

Share

Kalyan Kumar Pasunooti, 5-Methylisoxazole-3-carboxamide-Directed Palladium-Catalyzed γ-C(sp3)–H Acetoxylation and Application to the Synthesis of γ-Mercapto Amino Acids for Native Chemical Ligation

 Uncategorized  Comments Off on Kalyan Kumar Pasunooti, 5-Methylisoxazole-3-carboxamide-Directed Palladium-Catalyzed γ-C(sp3)–H Acetoxylation and Application to the Synthesis of γ-Mercapto Amino Acids for Native Chemical Ligation
Oct 132018
 
Abstract Image

Palladium-catalyzed acetoxylation of the primary γ-C(sp3)–H bonds in the amino acids Val, Thr, and Ile was achieved using a newly discovered 5-methylisoxazole-3-carboxamide directing group. The γ-acetoxylated α-amino acid derivatives could be easily converted to γ-mercapto amino acids, which are useful for native chemical ligation (NCL). The first application of NCL at isoleucine in the semisynthesis of a Xenopus histone H3 protein was also demonstrated.

5-Methylisoxazole-3-carboxamide-Directed Palladium-Catalyzed γ-C(sp3)–H Acetoxylation and Application to the Synthesis of γ-Mercapto Amino Acids for Native Chemical Ligation

School of Biological Sciences, Nanyang Technological UniversitySingapore 637551
Org. Lett.201618 (11), pp 2696–2699
DOI: 10.1021/acs.orglett.6b01160
Publication Date (Web): May 24, 2016
Copyright © 2016 American Chemical Society
*E-mail: cfliu@ntu.edu.sg.

link

https://pubs.acs.org/doi/abs/10.1021/acs.orglett.6b01160

hps://pubs.acs.org/doi/suppl/10.1021/acs.orgletttt.6b01160/suppl_file/ol6b01160_si_001.pdf

str3 str1 str2

 

Kalyan_Pasunooti2

 

Kalyan Kumar Pasunooti,

kalyan kumar <kalyandrf@gmail.com>

Dr. Kalyan Kumar Pasunooti pursued his PhD degree from Nanyang Technological University (NTU) (www.ntu.edu.sg), Singapore (2007 – 2011) in the field of Medicinal, Peptide & Protein chemistry. His graduate research work is focused on “Synthesis of bioactive amino acid building blocks and their applications towards the peptides and glycopeptides.” His have total 16 years of academic and industry experience with major multinationals companies & academic institutions and have worked with many collaborative professors around the globe. He authored with more than 28 international peer-reviewed high impact publications such as PNAS, Wily (Angew Chemie), RSC (Chem Comm and Org Biomol Chem), most of American Chemical Society journals (Journal of American Chemical Society, Org. Lett., ACS Chem Bio, J Comb Chem and Bioconugate Chem) and Elsevier (Tetrahedron Letters) journals which are featured many times in Chem. Eng. News and other journals. He holds American patent while work with Johns Hopkins-School of Medicine, USA and this molecule in phase II clinical trials for treating cancer.

Prior to his graduate studies, he spent 5 years as a research scientist in reputable research organizations namely GVK Bio, India (www.gvkbio.com) (2006-2007) and Dr. Reddy’s Laboratories Ltd (www.drreddys.com) (2003-2006) in India. After his PhD graduation, he worked for world leading research institutes such as Johns Hopkins-School of Medicine, USA (www.hopkinsmedicne.org) (2012-2013), Nanyang Technological University-NTU, Singapore) (www.ntu.edu.sg) (2013 – 2017) and Singapore MIT Alliance for research & Technology-SMART (www.smart.mit.edu) (2017–2018). His research interests focused on development of next generation biologically relevant peptide & protein therapeutics using their newly discovered methodologies for biomedical applications.

He has excellent skills in designing synthesis, purification and characterization of complex peptide and small molecules for medicinal chemistry applications. He gained extensive experience in Medicinal, Carbohydrate, Peptide & Protein and nucleotide & nucleoside Chemistry and familiar with modern methods and experienced in designing & executing synthesis for various bioactive peptide and small molecule inhibitors. He well versed in synthesis and characterization of complex organic molecules and with the analytical data interpretation.

 

Dr. Kalyan Kumar Pasunooti

Research Scientist at Singapore-MIT Alliance for Research & Technology Centre

Singapore’

Accomplished Peptide, Protein and Medicinal chemist with 16 years of academic and industrialexperience in the field of drug discovery and development. Specializations: Peptide & Protein Chemistry,Medicinal Chemistry (Drug Discovery and Development) and Chemical Biology.

ExperienceSingapore-MIT Alliance for Research & Technology Centre

Research Scientist

  • Company NameSingapore-MIT Alliance for Research & Technology Centre

    Dates EmployedJul 2017 – Present

    Employment Duration1 yr 4 mos

    LocationSingapore

    Medicinal Chemistry and Drug Discovery

  • Research Fellow

    Company NameNanyang Technological University, Singapore

    Dates EmployedOct 2013 – Jun 2017

    Employment Duration3 yrs 9 mos

    LocationSingapore

    Peptide & Protein Chemistry and Medicinal Chemistry

  • Postdoctoral Fellow

    Company NameJohns Hopkins Medicine

    Dates EmployedMay 2012 – Sep 2013

    Employment Duration1 yr 5 mos

    LocationBaltimore, Maryland Area

    Medicinal chemistry, Drug Discovery, Pharmacology and Chemical Biology

  • Postdoctoral Associate

    Company NameNanyang Technological University

    Dates EmployedJul 2011 – Mar 2012

    Employment Duration9 mos

    LocationSingapore

    Organic synthesis, Peptide & Carbohydrate chemistry and Medicinal chemistry.

  • Senior Research Associate in Medicinal Chemistry

    Company NameGVK Biosciences

    Dates EmployedJan 2007 – Jul 2007

    Employment Duration7 mos

    LocationHyderabad Area, India

    Synthesis of bioactive molecules for medicinal chemistry applications.

  • Junior Scientist in Medicinal Chemistry (Anti-Infective group)

    Company NameDr. Reddy’s Laboratories

    Dates EmployedAug 2003 – Dec 2006

    Employment Duration3 yrs 5 mos

    LocationHyderabad Area, India

    Medicinal chemistry (Anti-Infective group): My work entails design and synthesis of newoxazolidinone derivatives and new chemical entities as novel antibacterial agents. As a researchscientist my job demanded me to carry out extensive literature survey to design possible syntheticroutes for a proposed molecule and to carry out the total synthetic part in the laborator… See more

  • Education

    ////////

    READ

    ANTHONY MELVIN CRASTO

    https://newdrugapprovals.org/

    NDA

    DRUG APPROVALS BY DR ANTHONY MELVIN CRASTO …..FOR BLOG HOME CLICK HERE

    Join me on Linkedin

    View Anthony Melvin Crasto Ph.D's profile on LinkedIn

    Join me on Facebook FACEBOOK

    Join me on twitterFollow amcrasto on Twitter
    Join me on google plus Googleplus

     amcrasto@gmail.com

    CALL +919323115463  INDIA

    //////////////

    Share

    Quetiapine

     spectroscopy  Comments Off on Quetiapine
    Oct 092018
     

    Image result for quetiapine

    Quetiapine

    1H NMR (400 MHz, CD3OD): δ = 3.18-3.27 (m, 4H), 3.35-3.44 (m, 3H), 3.56-3.58 (m, 3H), 3.67-3.69 (m, 3H), 3.76 (t, J = 5.2 Hz, 2H), 4.32 (s, 1H), 6.88 (td, J = 7.4 Hz, 1.2 Hz, 1H), 7.04 (dd, J = 7.8 Hz, 1.6 Hz, 1H), 7.13 (td, J = 7.8 Hz, 1.6 Hz, 1H), 7.23 (dd, J = 6.8 Hz, 2.4 Hz, 1H), 7.28-7.39 (m, 4H) ppm.

    13C NMR (100 MHz, CD3OD): δ = 40.2, 45.6, 52.8, 53.3, 57.6, 62.0, 65.6, 73.4, 123.9, 125.99, 126.0, 128.4, 129.0, 130.6, 131.3, 132.5, 133.2, 134.7, 137.9, 145.7, 170.6 ppm.

     

    HRMS (ESI+ ): calcd for C21H26N3O2S [M+H]+ 384.1740, found 384.1735.

     

    STR1

    STR2

     

    Org. Lett., Article ASAP
    DOI: 10.1021/acs.orglett.8b02812

    /////////////

    Share

    2-amino-4-bromo-5-fluorobenzoic acid

     spectroscopy  Comments Off on 2-amino-4-bromo-5-fluorobenzoic acid
    Oct 092018
     

     

    Image result for 2-amino-4-bromo-5-fluorobenzoic acid

     

    STR1 STR2

    2-amino-4-bromo-5-fluorobenzoic acid as a white to off-white crystalline solid

    1H NMR (400 MHz, DMSO-d6) δ 7.62 (d, J=9.6 Hz, 1H), 7.21-6.5 (m, 3H), 3.8- 3.3 (br s, 1H).

    13C NMR (100 MHz, DMSO-d6) δ 170.5, 149.6, 147.6, 147.3, 120.4, 118.1, 118.0, 109.2, 109.0, 99.5.

    mp >250 °C. IR (neat) 3494, 3351, 3053, 3038, 1521, 774 cm-1;

    HRMS (ESI) m/z: calcd for C7H5BrFNO2 [M+H]+ 233.9560, found 233.9551.

    Org. Lett.201820 (13), pp 3736–3740
    DOI: 10.1021/acs.orglett.8b01218
    1H NMR AND 13C NMR PREDICT
    STR1 STR2

    ////////////

    Share

    4-(2-fluoro-4-nitrophenyl)morpholine

     Uncategorized  Comments Off on 4-(2-fluoro-4-nitrophenyl)morpholine
    Sep 202018
     

    str3 str4

    4-(2-fluoro-4-nitrophenyl)morpholine

    1H NMR (400MHz, CDCl3)  8.03 (ddd J=1.0, 2.6 and 9.0Hz, 1H, ArH), 7.94 (dd J=2.6 and 13.1Hz, 1H, ArH), 6.94 (t J=8.7Hz, 1H, ArH), 3.90 (t J=4.7Hz, 4H, 2xCH2O), 3.31 (m, 4H, 2xCH2N).

    13C NMR (100MHz, CDCl3)  153.3 (d J=249.5), 145.6 (d J=7.8Hz), 121.1 (d J=3.0Hz), 117.0 (d J=3.9Hz), 112.7 (d J=6.4Hz), 66.7, 50.0 (d J=4.9Hz).

    HRMS [M] Calcd for C10H11FN2O3 226.0748, Found 226.0749.

     

    Catalytic Static Mixers for the Continuous Flow Hydrogenation of a Key Intermediate of Linezolid (Zyvox)

    James GardinerXuan NguyenCharlotte GenetMike D. HorneChristian H. Hornung, and John Tsanaktsidis

    Org. Process Res. Dev., Article ASAP

    DOI: 10.1021/acs.oprd.8b00153

    ////////////////////

    Share

    3-fluoro-4- morpholinoaniline

     Uncategorized  Comments Off on 3-fluoro-4- morpholinoaniline
    Sep 202018
     

    STR1 STR2

    3-fluoro-4- morpholinoaniline
    1H NMR (400MHz, CDCl3)  6.82 (m, 1H, ArH), 6.43 (m, 2H, 2xArH), 3.87 (m, 4H, 2xCH2O), 3.58 (brs, 2H, NH2), 2.99 (m, 4H, 2xCH2N). 13C NMR (100MHz, CDCl3)  156.9 (d J= 245.4Hz), 143.0 (d J=10.4Hz), 131.8 (d J=9.7Hz), 120.4 (d J=4.2Hz), 110.8 (d J=3.0Hz), 104.0 (d J=23.8Hz), 67.3, 51.9 (d J=2.1Hz). HRMS [M] Calcd for C10H13FN2O 196.1006, Found 196.1004.
    Org. Process Res. Dev., Article ASAP
    DOI: 10.1021/acs.oprd.8b00153

     

    ////////////////////

    Share

    A call to (green) arms: a rallying cry for green chemistry and engineering for CO2 capture, utilisation and storage

     green chemistry  Comments Off on A call to (green) arms: a rallying cry for green chemistry and engineering for CO2 capture, utilisation and storage
    Sep 172018
     

    Graphical abstract: A call to (green) arms: a rallying cry for green chemistry and engineering for CO2 capture, utilisation and storage

    A call to (green) arms: a rallying cry for green chemistry and engineering for CO2 capture, utilisation and storage

     Author affiliations

    Abstract

    Chemists, engineers, scientists, lend us your ears… Carbon capture, utilisation, and storage (CCUS) is among the largest challenges on the horizon and we need your help. In this perspective, we focus on identifying the critical research needs to make CCUS a reality, with an emphasis on how the principles of green chemistry (GC) and green engineering can be used to help address this challenge. We identify areas where GC principles can readily improve the energy or atom efficiency of processes or reduce the environmental impact. Conversely, we also identify dilemmas where the research needs may be at odds with GC principles, and present potential paths forward to minimise the environmental impacts of chemicals and processes needed for CCUS. We also walk a different path from conventional perspectives in that we postulate and introduce potential innovative research directions and concepts (some not yet experimentally validated) in order to foster innovation, or at least stoke conversation and question why certain approaches have not yet been attempted. With elements of historical context, technological innovation, critical thinking, and some humour, we issue a call to arms and hope you may join us in this fight.

    http://pubs.rsc.org/en/Content/ArticleLanding/2018/GC/C8GC01962B?utm_source=feedburner&utm_medium=feed&utm_campaign=Feed%3A+rss%2FGC+%28RSC+-+Green+Chem.+latest+articles%29#!divAbstract

    STR1

    Julien Leclaire

    David Heldebrant

    David Heldebrant

    Pacific Northwest National Laboratory
    PO Box 999
    Richland, WA 99352

    /////////

    Share

    Development of an SNAr Reaction: A Practical and Scalable Strategy To Sequester and Remove HF

     organic chemistry, SYNTHESIS  Comments Off on Development of an SNAr Reaction: A Practical and Scalable Strategy To Sequester and Remove HF
    Sep 142018
     

    Abstract Image

    A simple and operationally practical method to sequester and remove fluoride generated through the SNAr reaction between amines and aryl fluorides is reported. Calcium propionate acts as an inexpensive and environmentally benign in situ scrubber of the hydrofluoric acid byproduct, which is simply precipitated and filtered from the reaction mixture during standard aqueous workup. The method has been tested from 10 to 100 g scale of operation, showing >99.5% decrease in fluoride content in each case. Full mass recovery of calcium fluoride is demonstrated at both scales, proving this to be a general, efficient, and robust method of fluoride abstraction to help prevent corrosion of glass-lined reactors.

    Development of an SNAr Reaction: A Practical and Scalable Strategy To Sequester and Remove HF

     Institute of Process Research and Development, School of Chemistry and School of Chemical and Process EngineeringUniversity of Leeds, Leeds LS2 9JT, United Kingdom
     Chemical DevelopmentAstraZeneca, Macclesfield SK10 2NA, United Kingdom
    Org. Process Res. Dev., Article ASAP
    DOI: 10.1021/acs.oprd.8b00090

    ///////////////aryl amines, calcium fluoride, fluoride sequestration, scale-up, SNAr reaction,

    “ALL FOR DRUGS” CATERS TO EDUCATION GLOBALLY, No commercial exploits are done or advertisements added by me. This is a compilation for educational purposes only. P.S. : The views expressed are my personal and in no-way suggest the views of the professional body or the company that I represent
    Share

    1-(4-Cyanophenyl)piperazine

     spectroscopy  Comments Off on 1-(4-Cyanophenyl)piperazine
    Sep 142018
     

    STR1

    1-(4-Cyanophenyl)piperazine

    1-(4-Cyanophenyl)piperazine (1a).1 Isolated as a mixture of mono (1a) and di (3) arylated products ~9:1. Conversion: quantitative. Peaks attributed to 1a: 1H NMR (400 MHz, CD3Cl) δH 7.47 (m, 2H, arH), 6.83 (m, 2H, ar-H), 3.26 (m, 4H, pip-H), 2.99 (m, 4H, pip-H), 1.69 (br s, 1H, NH). Peaks attributed to 3: 7.52 (d, J = 9.0 Hz, 4H, ar-H), 6.88 (d, J = 9.0 Hz, 4H, ar-H), 3.29 (s, 8H, pip-H).

    Org. Process Res. Dev., Article ASAP
    DOI: 10.1021/acs.oprd.8b00090

    //////////////

    https://pubs.acs.org/doi/suppl/10.1021/acs.oprd.8b00090/suppl_file/op8b00090_si_001.pdf

    Share

    Crystallization

     Uncategorized  Comments Off on Crystallization
    Sep 122018
     

    Image result for Crystallization

    Crystallization is the (natural or artificial) process by which a solid forms, where the atoms or molecules are highly organized into a structure known as a crystal. Some of the ways by which crystals form are precipitating from a solutionfreezing, or more rarely depositiondirectly from a gas. Attributes of the resulting crystal depend largely on factors such as temperature, air pressure, and in the case of liquid crystals, time of fluid evaporation.

    Crystallization occurs in two major steps. The first is nucleation, the appearance of a crystalline phase from either a supercooled liquid or a supersaturated solvent. The second step is known as crystal growth, which is the increase in the size of particles and leads to a crystal state. An important feature of this step is that loose particles form layers at the crystal’s surface lodge themselves into open inconsistencies such as pores, cracks, etc.

    The majority of minerals and organic molecules crystallize easily, and the resulting crystals are generally of good quality, i.e. without visible defects. However, larger biochemical particles, like proteins, are often difficult to crystallize. The ease with which molecules will crystallize strongly depends on the intensity of either atomic forces (in the case of mineral substances), intermolecular forces (organic and biochemical substances) or intramolecular forces (biochemical substances).

    Crystallization is also a chemical solid–liquid separation technique, in which mass transfer of a solute from the liquid solution to a pure solid crystalline phase occurs. In chemical engineering, crystallization occurs in a crystallizer. Crystallization is therefore related to precipitation, although the result is not amorphous or disordered, but a crystal.

    The design of a successful crystallization process depends on choosing process parameters that will produce crystals of the required purity and yield, that can be isolated, filtered, and dried easily. Process parameters such as cooling rate, solvent composition, and agitation rate directly impact crystallization behavior. Scientists are tasked with understanding how these parameters will influence the outcome of the crystallization process. Often, process parameters for crystallization are chosen based on previous experience, and the outcome is determined by careful analysis of offline analytical data, such as particle size analysis, XRPD, or microscopy. This approach is common, but neglects to consider that crystallization occurs through a sequence of interdependent mechanisms which all contribute to the final outcome, and are each uniquely influenced by the choice of process parameters.

    Crystal nucleation and growth, phase separation, breakage, agglomeration, and polymorph transformations can occur separately, but also simultaneously, and are influenced by process parameters in unique ways. This convolution of mechanisms can mask the true role process parameters play in determining the outcome of a crystallization process, and make crystallization process design a particular challenge for scientists. In the absence of mechanistic understanding for crystallization processes, scientists must often rely on trial-and-error to adjust process parameters and optimize yield, purity, and particle size. This can be a time-consuming task and is one that rarely delivers crystals that can be isolated, filtered, and dried in a facile manner.

    In this series of articles, the most common crystallization mechanisms are described alongside strategies to optimize them. The complete guide to crystallization mechanisms can be downloaded here.

    What is Nucleation?

    Nucleation occurs when solute molecules assemble in a supersaturated solution and reach a critical size. Primary nucleation occurs when nuclei appear from a solution directly and secondary nucleation occurs when nulcei appear in the presence of solids. Nucleation is important to understand because the number and size of nuclei formed can have a dominant influence on the final outcome of the crystallization process. High nucleation rates can lead to excessive fines and a bimodal crystal population which can make product isolation, filtration, and further processing difficult.

    Considerations for Control

    The nucleation rate is dependent on the molecule being crystallized but can be manipulated by considering the solvent type, controlling the supersaturation level, and evaluating the role of impurities and mixing during crystallization design. Seeding is a common strategy deployed to control primary nucleation. Effective seeding can initiate nucleation at a consistent point, and by choosing the seed size and seed loading the nucleation rate can be controlled.

    Secondary nucleation often occurs during a crystallization process when supersaturation increases above a critical limit. This can occur when cooling is too fast or when anti-solvent is added quickly in an effort to increase yield. Secondary nucleation is particularly critical to understand and control because it can suddenly appear during scale-up when process parameters are controlled with less precision compared to the lab

    Key Crystallization Definitions

    Crystallization
    Crystallization is a process whereby solid crystals are formed from another phase, typically a liquid solution or melt.

    Crystal
    Crystal is a solid particle in which the constituent molecules, atoms, or ions are arranged in some fixed and rigid, repeating three-dimensional pattern or lattice.

    Precipitation
    Precipitation is another word for crystallization but is most often used when crystallization occurs very quickly through a chemical reaction.

    Solubility
    Solubility is a measure of the amount of solute that can be dissolved in a given solvent at a given temperature

    Saturated Solution
    At a given temperature, there is a maximum amount of solute that can be dissolved in the solvent. At this point the solution is saturated. The quantity of solute dissolved at this point is the solubility.

    Supersaturation
    Supersaturation is the difference between the actual solute concentration and the equilibrium solute concentration at a given temperature.

    Crystallization
    Process-of-Crystallization-200px.png
    Concepts
    Crystallization · Crystal growth
    Recrystallization · Seed crystal
    Protocrystalline · Single crystal
    Methods and technology
    Boules
    Bridgman–Stockbarger technique
    Crystal bar process
    Czochralski process
    Epitaxy
    Flux method
    Fractional crystallization
    Fractional freezing
    Hydrothermal synthesis
    Kyropoulos process
    Laser-heated pedestal growth
    Micro-pulling-down
    Shaping processes in crystal growth
    Skull crucible
    Verneuil process
    Zone melting
    Fundamentals
    Nucleation · Crystal
    Crystal structure · Solid

    Busting a myth about mechanochemical crystallization

    Adding varying amounts of liquid yields multiple crystal forms
    Chart and structures showing the different phases of caffeine and anthranilic acid cocrystals that are produced when different amounts of ethanol are added.
    Credit: Cryst. Growth Des.

    [+]Enlarge

    Chart and structures showing the different phases of caffeine and anthranilic acid cocrystals that are produced when different amounts of ethanol are added.
    Mechanochemical crystallization of caffeine and anthranilic acid yields polymorph I, polymorph II, or a mixture, depending on the amount of ethanol added.
    Credit: Cryst. Growth Des.

    Although it may seem counterintuitive to put a compound into a ball mill to turn it into a crystalline form, the approach nonetheless works—and adding varying amounts of liquid can determine the crystal form that results, reports a team led by Bill Jones of the University of Cambridge (Cryst. Growth Des.2016, DOI: 10.1021/acs.cgd.6b00682).

    Compounds of interest for materials and pharmaceuticals applications often crystallize into different forms, called polymorphs. Because polymorphs can have varying stability, solubility, and other properties, forming a specific polymorph can be critically important.

    Chemists have long thought that using one particular liquid when crystallizing compounds via mechanochemical milling always yields one particular polymorph. Seeking to test that dogma, Jones and coworkers crystallized 200 mg of a 1:1 equimolar mixture of caffeine and anthranilic acid using a ball mill, adding from 10 to 100 μL of 15 different liquids.

    Four liquids—acetonitrile, nitromethane, ethylene glycol, and 1,6-hexanediol—formed one polymorph each, regardless of the amount of liquid. The rest of the liquids yielded different polymorphs or mixtures, depending on liquid volume: 10 to 20 μL of ethanol formed polymorph II, for example, whereas 40 to 60 μL formed polymorph I. Additionally, 10 μL of 1-hexanol, 1-octanol, or 1-dodecanol formed polymorph III, a polymorph previously only prepared by desolvation.

    Similar effects could occur for single-component crystals, the authors say. The mechanism behind the phenomenon remains to be determined; the authors suggest that it could be a result of thermodynamic stabilization of nanoparticles, different growth mechanisms of the polymorphs, or changes in the free-energy difference between polymorphs caused by milling conditions.

    See also

    References

    1. Jump up^ Lin, Yibin (2008). “An Extensive Study of Protein Phase Diagram Modification:Increasing Macromolecular Crystallizability by Temperature Screening”. Crystal Growth & Design8 (12): 4277. doi:10.1021/cg800698p.
    2. Jump up^ Chayen, Blow (1992). “Microbatch crystallization under oil — a new technique allowing many small-volume crystallization trials”. Journal of Crystal Growth122 (1-4): 176-180. Bibcode:1992JCrGr.122..176Cdoi:10.1016/0022-0248(92)90241-A.
    3. Jump up^ Benvenuti, Mangani (2007). “Crystallization of soluble proteins in vapor diffusion for x-ray crystallography”. Nature Protocols2: 1663. doi:10.1038/nprot.2007.198.
    4. Jump up to:a b Tavare, N. S. (1995). Industrial Crystallization. Plenum Press, New York.
    5. Jump up to:a b McCabe & Smith (2000). Unit Operations of Chemical Engineering. McGraw-Hill, New York.
    6. Jump up^ “Crystallization”www.reciprocalnet.orgArchived from the original on 2016-11-27. Retrieved 2017-01-03.
    7. Jump up^ “Submerge Circulating Crystallizers – Thermal Kinetics Engineering, PLLC”Thermal Kinetics Engineering, PLLC. Retrieved 2017-01-03.
    8. Jump up^ “Draft Tube Baffle (DTB) Crystallizer – Swenson Technology”Swenson TechnologyArchived from the original on 2016-09-25. Retrieved 2017-01-03.

    Further reading

    • A. Mersmann, Crystallization Technology Handbook (2001) CRC; 2nd ed. ISBN0-8247-0528-9
    • Tine Arkenbout-de Vroome, Melt Crystallization Technology (1995) CRC ISBN1-56676-181-6
    • “Small Molecule Crystallization” (PDF) at Illinois Institute of Technology website
    • Glynn P.D. and Reardon E.J. (1990) “Solid-solution aqueous-solution equilibria: thermodynamic theory and representation”. Amer. J. Sci. 290, 164–201.
    • Geankoplis, C.J. (2003) “Transport Processes and Separation Process Principles”. 4th Ed. Prentice-Hall Inc.
    • S.J. Jancic, P.A.M. Grootscholten: “Industrial Crystallization”, Textbook, Delft University Press and Reidel Publishing Company, Delft, The Netherlands, 1984.

    External links

    Crystallization Publications

    Discover a selection of crystallization publications below:

    The seminal study on the nucleation of crystals from solution
    Jaroslav Nývlt, Kinetics of nucleation in solutions, Journal of Crystal Growth, Volumes 3–4, 1968.

    Excellent study on how crystals grow form solution
    Crystal Growth Kinetics, Material Science and Engineering, Volume 65, Issue 1, July 1984.

    An excellent description of the reasons solute-solvent systems exhibit oiling out instead of crystallization
    Kiesow et al., Experimental investigation of oiling out during crystallization process, Journal of Crystal Growth, Volume 310, Issue 18, 2008.

    Detailed examination of why agglomeration occurs during crystallization
    Brunsteiner et al., Toward a Molecular Understanding of Crystal Agglomeration, Crystal Growth & Design, 2005, 5 (1), pp 3–16.

    A study of breakage mechanisms during crystallization
    Fasoli & Conti, Crystal breakage in a mixed suspension crystallizer, Volume 8, Issue8, 1973, Pages 931-946.

    A great overview of how to design effective crystallization processes in the high value chemicals industry
    Paul et al., Organic Crystallization Processes, Powder Technology, Volume 150, Issue 2, 2005.

    Techniques to ensure the correct polymorph is crystallized every time
    Kitamura, Strategies for Control of Crystallization of Polymorphs, CrystEngComm, 2009,11, 949-964.

    ////////////////

    Share
    Follow

    Get every new post on this blog delivered to your Inbox.

    Join other followers: